Dormant copies of HIV mostly defective, new study shows

August 8, 2016, Johns Hopkins University School of Medicine
HIV infecting a human cell. Credit: NIH

After fully sequencing the latent HIV "provirus" genomes from 19 people being treated for HIV, scientists at Johns Hopkins Medicine report that even in patients who start treatment very early, the only widely available method to measure the reservoir of dormant HIV in patients is mostly counting defective viruses that won't cause harm, rather than those that can spring back into action and keep infections going.

Specifically, the investigators showed that more than 90 percent of latent proviruses are genetic duds, so mutated—even in early stages of disease—that they no longer function. The findings, described August 8 in Nature Medicine online, suggest a pressing need for new ways to count only non-damaged proviruses, because an accurate count is key to guiding and gauging the effectiveness of experimental therapies directed at the latent HIV reservoir.

"To cure HIV, you want to get rid of the proviruses without defects," says senior study author Robert Siliciano, M.D., Ph.D., an infectious disease physician and molecular biologist at the Johns Hopkins University School of Medicine. "But our work shows that the standard assays used to do that are measuring forms of the virus that are not really relevant to these cure strategies."

HIV infection is currently treated with antiretroviral therapies (ART) that are effective in blocking the virus from copying itself to produce more viruses. But the virus persists because in its latent form, it successfully hides inside certain immune system cells without actively replicating and without producing chemical signals that make the virus targets of ART.

However, proviruses can and do become active, causing a new flare of infection in who have stopped ART. Efforts to knock out the latent virus reservoirs—so far unsuccessful—have become something of a Holy Grail to virologists, Siliciano notes.

To test the effectiveness of new, experimental drug strategies that aim to cure HIV by eliminating the proviruses, he adds, scientists typically take "snapshots" of the provirus reservoir levels before and after treatments are given. Most often, they use a technique called polymerase chain reaction (PCR) to quantify the presence of certain tell-tale HIV genes. But even defective proviruses—as long as they still contain the genes being tallied—are counted.

Until now, however, researchers didn't think that was always a problem. "Most of us in the field assumed that the initial pool of latent proviruses, immediately after infection, contained entirely functional copies of the virus, so we also assumed that PCR—at least for patients treated with ART early in the course of infection—would mostly be counting proviruses that had the ability to cause disease again," says Katherine Bruner, a graduate student in Siliciano's laboratory and first author of the new paper. For patients further along in the course of their disease when they began ART treatment, however, researchers suspected that a bigger percentage of latent viruses were likely to be defective. A fraction of the proviruses that are not defective can be detected by a more laborious method, called a quantitative viral outgrowth assay (QVOA), which was considered the best way to measure the size of the reservoir.

Wondering whether either technique was accurately counting potentially trouble-making HIV proviruses, Siliciano, Bruner, and their colleagues sequenced the full genomes of a large number of proviruses from 19 men and women of various races between the ages of 20 and 76 who had started ART either less than 100 days after infection or more than 180 days after. All had been on ART for at least eight months.

Between 90 and 98 percent of the proviruses from any one patient, the researchers found, were defective and incapable of replicating to become an active virus. The results held true whether the patients had started ART within weeks or years of contracting HIV.

"Even in patients treated really early, if you're using a PCR-based approach to measure the reservoir, you're really just detecting a lot of defective proviruses," says Bruner.

When the research team compared the full sequencing data with analyses of the same patients' proviruses conducted with PCR or QVOA, they showed that PCR overestimates the true size of the latent reservoir by a median of 188-fold in patients who began treatment more than six months after their infection with HIV, and 13-fold in patients who began treatment earlier, while QVOA underestimates the reservoir by a median of 27-fold in patients who began treatment late and 25-fold in those who began treatment early.

The full sequencing method used in their new research, Bruner says, "is very helpful from a research standpoint but time-consuming, expensive, and impractical for wide clinical use." So, for now, the two inaccurate standbys are all that researchers have, she says.

Bruner and Siliciano say they hope their results—showing that patients harbor substantially more defective proviruses than previously thought, and that these defective proviruses accumulate almost immediately after infection—will help researchers to better understand what the PCR and QVOA results really mean.

"With current counting methods, it looks like you can bracket the true size range," says Siliciano. "But we'd like to figure out better ways to do the measurements."

More than 36 million people worldwide are living with HIV and 17 million are currently being treated with ART, according to the latest estimates from the UN. Around 1.2 million people in the U.S. have the disease. Researchers are following multiple lines of research that aim to develop cures for the infection by targeting the latent reservoir, including compounds that keep the proviruses permanently suppressed, those that force them to be activated so ART or the immune system can block them, and approaches that target the T cells where the latent virus hides.

Explore further: Scientists discover that defective HIV DNA can encode HIV-related proteins

More information: Defective proviruses rapidly accumulate during acute HIV-1 infection, Nature Medicine , DOI: 10.1038/nm.4156

Related Stories

Scientists discover that defective HIV DNA can encode HIV-related proteins

July 18, 2016
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template ...

Reservoir of hidden HIV larger than previously thought

October 24, 2013
In the fight to cure human immunodeficiency virus (HIV), researchers have been dealt a blow. A new study by Howard Hughes Medical Institute (HHMI) scientists discovered that the pool of inactive HIV viruses that lingers silently ...

Early antiretroviral therapy dramatically reduces HIV DNA set point

August 1, 2016
A team of researchers, led by Drs. Merlin Robb and Jintanat Ananworanich of the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research, has found that when antiretroviral therapy (ART) is ...

Study observes potential breakthrough in treatment of HIV

June 17, 2016
A new study conducted by researchers at the San Francisco VA Medical Center (SFVAMC) observes that pharmacological enhancement of the immune systems of HIV patients could help eliminate infected cells, providing an important ...

Targeting HIV 'reservoir' could be first step to understanding how to cure the disease

December 1, 2015
A new clinical trial will test whether it is possible to destroy hidden reservoirs of HIV virus that are a key obstacle to curing the disease.

Researchers find tough new obstacle to HIV cure strategies

February 15, 2016
(Medical Xpress)—It's a good news/bad news scenario: Researchers have made a new discovery about HIV that will redirect curative strategies toward latent reservoirs of HIV—that's the good news. The bad news is that they ...

Recommended for you

Researchers find new way to defeat HIV latency

March 8, 2018
HIV, the virus that causes AIDS, has a secret life. Though anti-retroviral therapy can reduce its numbers, the virus can hide and avoid both treatments and the body's immune response.

Broadly neutralizing antibody treatment may target viral reservoir in monkeys

March 5, 2018
After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed ...

HIV begins to yield secrets of how it hides in cells

March 2, 2018
UC San Francisco scientists have uncovered new mechanisms by which HIV hides in infected cells, resting in a latent state that evades the body's immune system and prevents antiviral drugs from flushing it out.

HIV exports viral protein in cellular packages

February 15, 2018
HIV may be able to affect cells it can't directly infect by packaging a key protein within the host's cellular mail and sending it out into the body, according to a new study out of a University of North Carolina Lineberger ...

Can gene therapy be harnessed to fight the AIDS virus?

February 13, 2018
For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell's HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible.

Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018
Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.